trending Market Intelligence /marketintelligence/en/news-insights/trending/HBewi0PSRx8qI35lO-ANQg2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Generation Bio closes $110M series C round

Banking Essentials Newsletter December Edition Part 2

Banking Essentials Newsletter - November Edition

University Essentials | COVID-19 Economic Outlook in Banking: Rates and Long-Term Expectations: Q&A with the Experts

Estimating Credit Losses Under COVID-19 and the Post-Crisis Recovery


Generation Bio closes $110M series C round

Generation Bio Co. secured $110 million in series C funding led by T. Rowe Price Group Inc. funds and accounts.

Farallon Capital Management LLC and Wellington Management Co. LLP also participated in the round, alongside existing backers Atlas Venture LP, Fidelity Management & Research Co., The Invus Group LLC, Casdin Capital LLC, Deerfield Management Co. LP, Foresite Capital Management LLC and an entity related to SVB Leerink LLC.

The gene therapy-focused biotechnology company will use the new capital to move its two liver-targeted programs for hemophilia A and phenylketonuria into investigational new drug-enabling studies and clinical development.

Cowen was the exclusive placement agent for the funding round.